Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA
Articles by Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA
ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS
ByRyan Haumschild, PharmD, MS, MBA,James McCloskey, MD ,Amer Zeidan, MD,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Tracey Iraca Medical experts discuss the data gathered from the ASCERTAIN trial.
Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial
ByRyan Haumschild, PharmD, MS, MBA,James McCloskey, MD ,Amer Zeidan, MD,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Tracey Iraca Medical experts offer insights on the COMMANDS trial findings.
Choosing MDS Therapies: Risk-Based Approaches
ByRyan Haumschild, PharmD, MS, MBA,James McCloskey, MD ,Amer Zeidan, MD,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Tracey Iraca Medical experts discuss risk-based approaches to choosing MDS therapies.
Advances in MDS Classification and Molecular Understanding
ByRyan Haumschild, PharmD, MS, MBA,James McCloskey, MD ,Amer Zeidan, MD,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Tracey Iraca After a brief introduction, medical experts discuss advances in MDS classification and molecular understanding.
